Tracy Frech

Colonic bacterial composition in Parkinson's disease

Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study

Shared and distinct mechanisms of fibrosis

Systemic sclerosis-associated interstitial lung disease

Stratification and compartmentalisation of immunoglobulin responses to commensal intestinal microbes

Mechanism and medical implications of mammalian autophagy

A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients

Macrophages in immunoregulation and therapeutics

Systemic sclerosis

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?

Systemic sclerosis

Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis

Gastrointestinal Manifestations, Malnutrition, and Role of Enteral and Parenteral Nutrition in Patients With Scleroderma

The pathogenesis, diagnosis and treatment of Raynaud phenomenon

Small intestinal bacterial overgrowth syndrome

Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician‐ and Patient‐Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS)

IRF3 and type I interferons fuel a fatal response to myocardial infarction

Nutritional status measured by BMI is impaired and correlates with left ventricular mass in patients with systemic sclerosis

Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐reported outcomes measurement information system 29‐item health profile and functional assessment of chronic illness therapy–dyspnea short form

Ulcerative colitis

Mitochondria as multifaceted regulators of cell death

Major lung complications of systemic sclerosis

Autophagy: controlling cell fate in rheumatic diseases

Systemic sclerosis

Microflora Modulation of Motility

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Seaweed extract stimuli in plant science and agriculture

Introduction to the human gut microbiota

Genetic and epigenetic abnormalities in systemic sclerosis

Gastrointestinal manifestations of systemic sclerosis

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis

Nutritional status and gastrointestinal symptoms in systemic sclerosis patients

Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology

The utility of nutraceuticals in the treatment of osteoarthritis

Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study

Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: A population‐based study

Autophagy is a key feature in the pathogenesis of systemic sclerosis

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis

Small intestinal bacterial overgrowth in systemic sclerosis

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale

Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.

Low-Dose Naltrexone for Pruritus in Systemic Sclerosis